A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group.
暂无分享,去创建一个
C. Haie-meder | F. Bertucci | B. Weber | I. Ray-Coquard | S. Piperno-Neumann | A. Floquet | P. Kerbrat | R. Largillier | F. Selle | N. Isambert | E. Bompas | F. Duffaud | L. Gladieff | P. Duvillard | P. Opinel | P. Pautier | C. Lhommé | C. Guillemet | G. Netter-Pinon | N. Pinto | A. Rey | C. Delcambre | A. Reynaud-Bougnoux | Bettina Weber
[1] E. Venkatraman,et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Wharton,et al. High‐dose doxorubicin infusion therapy for disseminated mixed mesodermal sarcoma of the uterus , 1987, Cancer.
[3] Horton,et al. Annals of Oncology , 1991, Springer US.
[4] M. van Glabbeke,et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] P. Disaia,et al. Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study. , 1986, Cancer treatment reports.
[6] R. Sylvester,et al. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data , 1997 .
[7] J. van Nagell,et al. Adjuvant vincristine, dactinomycin, and cyclophosphamide therapy in stage i uterine sarcomas. A pilot study , 1986, Cancer.
[8] M. Piver,et al. Cyclophosphamide, vincristine, adriamycin, and dimethyl-triazeno imidazole carboxamide (CYVADIC) for sarcomas of the female genital tract. , 1982, Gynecologic oncology.
[9] D. Crowther. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data , 1997, The Lancet.
[10] F. Farrokhyar,et al. A systematic meta‐analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft‐tissue sarcoma , 2008, Cancer.
[11] C. Haie-meder,et al. Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case‐control study with radiotherapy alone , 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
[12] S. Lifshitz,et al. Prophylactic chemotherapy in stages I and II uterine sarcoma. , 1979, Gynecologic oncology.
[13] G. Sutton,et al. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. , 1996, Gynecologic oncology.
[14] M. Piver,et al. Impact on Progression‐Free Survival of Adjuvant Cyclophosphamide, Vincristine, Doxorubicin (Adriamycin), and Dacarbazine (CYVADIC) Chemotherapy for Stage I Uterine Sarcoma: A Prospective Trial , 1995, American journal of clinical oncology.
[15] E. Yordan,et al. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] P. Disaia,et al. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). , 1989, American journal of obstetrics and gynecology.
[17] R. Zaino,et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas , 1983, Cancer.
[18] A. Tolcher,et al. Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma. , 2013, Annals of Oncology.
[19] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[20] M. Feldstein,et al. Uterine sarcomas. Natural history, treatment and prognosis , 1978, Cancer.
[21] C. Haie-meder,et al. Cisplatin‐based chemotherapy regimen (DECAV) for uterine sarcomas , 2002, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
[22] M. Franchi,et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). , 2008, European journal of cancer.
[23] D. Haynes,et al. Mixed Mesodermal Tumors of the Uterus , 1965, Southern medical journal.
[24] A. Cesne,et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] R. Freedman,et al. Adjuvant chemotherapy in early uterine sarcoma. , 1983, Gynecologic oncology.
[26] P. Sabbatini,et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. , 2009, Gynecologic oncology.
[27] C. Haie-meder,et al. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma , 2000, Cancer.
[28] C. Mangan,et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] J. Blay,et al. Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: A multivariate analysis of the French Sarcoma Group database. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] P. Disaia,et al. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin Versus doxorubicin and cyclophosphamide (a phase III trial of the gynecologic oncology group) , 1985, Cancer.
[31] G. Sutton,et al. Phase II trial of ifosfamide and mesna in leiomyosarcoma ofthe uterus: A Gynecologic Oncology Group study , 1992 .